Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pulls CLIA Waiver Guidance, CMS To Take Lead Drafting New Criteria

This article was originally published in The Gray Sheet

Executive Summary

The Centers for Medicare & Medicaid Services will have the authority to make the final call on whether products receive CLIA waiver, according to FDAers.
Advertisement

Related Content

CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
Industry CLIA Waiver Proposal Will Be Presented At CLIAC Meeting
Industry CLIA Waiver Proposal Will Be Presented At CLIAC Meeting
CLIAC Reaffirms Quality, Comparability In Waiver Criteria Proposal To HHS
CLIAC Reaffirms Quality, Comparability In Waiver Criteria Proposal To HHS
CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies
CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies
Advertisement
UsernamePublicRestriction

Register

MT015539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel